- Cannabis
users have historically preferred to inhale smoke from the burned plant in
order to achieve rapid-onset absorption of its properties, but Lexaria
Bioscience is making it possible to achieve similar results through oral
ingestion
- Lexaria’s
revolutionary DehydraTECH technology allows cannabis users to eliminate
the unhealthy effects of smoking from their routines, and the product is
being tested with nicotine as well
- Cannabis-infused
edibles sales are expected to climb from about $1 billion currently to
about $4.1 billion by 2022
Consumable bioactive product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will
expand the reach of its revolutionary DehydraTECH technology across the United
States courtesy of a definitive five-year agreement that allows B2B hemp
substance manufacturing firm Universal Hemp LLC to include it in many
cannabidiol (CBD)-based food ingredients.
Lexaria’s DehydraTECH is an ingested drug delivery platform
patented to work with all psychoactive and non-psychoactive cannabinoids (http://ibn.fm/qPDtt), making
them bioavailable through absorption at a rate comparable to the rapid-onset
effect of inhaled cannabis without the detrimental health effects that arise
from smoking. The Lexaria technology accomplishes this by speeding the rate of
absorption for chemicals in edibles – an otherwise slow means of making
substances bioavailable through the bloodstream.
DehydraTECH also allows the substances to be ingested
without the need for the unhealthy sweeteners that are commonly used in
cannabis-infused products to mask bitter tastes, according to the company.
The Universal Hemp agreement packages DehydraTECH with food
ingredients to be produced for the nutraceutical and consumer packaged goods
industries. In addition to the United States, outlets in Canada will be
included once that country’s regulations allow edible cannabis products.
“In terms of bioavailability, shelf stability and taste this
is the best performing technology in the market, hands down. Our corporate
customers cannot wait to put our water-soluble solution into their products!”
Universal Hemp CEO and Founder Chad Kahunahana stated in a news release about
the agreement (http://ibn.fm/SaAP7).
Chris Bunka, CEO of Lexaria Bioscience, noted that the
agreement’s new inroads to the hemp industry will not only deliver rapid
product uptake, but also allow the company to deliver precision dosing and
maximum product strength. Cannabis industry publication Green
Entrepreneur reported that cannabis-infused edibles sales reached over
$1 billion in 2018 and are expected to amount to about $4.1 billion by
2022 (http://ibn.fm/Ew9jX),
showing an exponential level of growth.
In addition, Lexaria also recently announced its entry into
a CBD beverage license agreement with Nic’s Beverages LLC for use in CBD-based
beverages to be produced and sold throughout the United States. Nic’s Beverages
will initially produce ready-to-drink (RTD) cold brew coffees enhanced with CBD
from multi-spectrum hemp oil (http://ibn.fm/HvuxQ).
Lexaria is the only company in the world to have a patent
issued for the oral delivery of all cannabinoids. DehydraTECH has received 11
patents in the United States and Australia, and it has about 60 additional
patents pending in more than 40 countries worldwide. The DehydraTECH platform
has also been used in research on nicotine absorption (http://ibn.fm/0D8wB).
The company’s informative July 11 investor conference video
on Virtual Investor Conferences’ series site is now accessible online, as noted
in a news release (http://ibn.fm/ysLBZ).
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
